T he p.Cys282Tyr (C282Y) substitution on the HFE gene is the main mutation associated with hemochromatosis. At the homozygous state, it is responsible for an inappropriately low production of hepcidin, the hormone regulating systemic iron, which results in increased serum iron levels and then in elevated transferrin saturation, the biochemical hallmark of the disease. 1 Increased transferrin saturation is directly related to the degree of hepcidin deficiency irrespective of total body iron stores, whereas increased serum ferritin levels inform on the amount of iron stored in excess. Once transferrin saturation exceeds 50%, nontransferrin bound iron (NTBI), a toxic form of iron, occurs. NTBI is avidly taken up by parenchymal cells and accounts for the constitution of iron excess in the liver, heart, and pancreas. 2 It is known to enhance the production of reactive oxygen species, which, in turn, leads to the damage of lipids, proteins, and DNA. 2 Thus, NTBI is thought to be involved in the occurrence and/or the worsening of iron-related symptoms.
The treatment of hemochromatosis relies on regular phlebotomies. All guidelines [3] [4] [5] [6] agree to treat patients as soon as serum ferritin levels exceed the upper normal limit. They recommend to obtain and then to maintain "low body iron stores." However, in the absence of evidence-based data, the definition of "low body iron stores" remains vague consisting of serum ferritin levels 50 mg/L, 4, 5 comprised between 50 and 100 mg/L 3 or "within the normal range." 6 Determination of transferrin saturation is not considered for the monitoring of phlebotomy therapy and no precise data are currently available on the evolution of transferrin saturation in patients on long-term maintenance therapy.
Even when recommended serum ferritin levels are achieved by maintenance therapy, patients remain at risk of developing or worsening general symptoms 7 and joint 8 symptoms, which greatly affects their quality of life. 9 We hypothesized that this could be, at least partly, related to sustained exposure to NTBI through long-term elevated transferrin saturation.
The present study was designed to precisely measure the respective variations of serum ferritin and transferrin saturation levels in a large sample of patients on maintenance therapy; and to determine whether the persistence of elevated transferrin saturation was associated with an increase in general and joint symptoms.
Patients and Methods

Inclusion Criteria
C282Y homozygotes were identified from LOGIFER, a database launched in 1989 and prospectively documented since then. Patients were eligible when fulfilling the following criteria: (1) age !18 years at diagnosis, (2) follow-up !3 years after the achievement of low body iron stores defined as the time when serum ferritin was first measured <50 mg/L and/or the weekly or bimonthly rhythm of phlebotomy therapy was abandoned, (3) availability of follow-up data (date and volume of phlebotomies, serum ferritin, transferrin saturation, and hemoglobin) including 1 paired measurement of both transferrin saturation and serum ferritin per year at least, and (4) last vital status as "alive" in December 2010. 10 
Data Collected
Data recorded at the time of diagnosis were extracted from LOGIFER and included year; sex; age; proband/ relative status; living area; alcohol consumption (nonexcessive [<30 g/day in males and <20 g/day in females] or excessive); tobacco smoking (nonsmoker or former/current smoker); increased blood pressure (antihypertensive therapy or blood pressure >140/90 mm Hg); body mass index (BMI, kg/m 2 ); diabetes (defined according to World Health Organization classification); transferrin saturation; and serum iron, transferrin, ferritin, aspartate aminotransferase, alanine aminotransferase, g-glutamyltransferase, and hemoglobin. Hepatic fibrosis was staged on liver biopsy according to the METAVIR scoring system 11 from 0 (no fibrosis) to 4 (definite cirrhosis), "severe fibrosis" referring to F3 and F4 stages. According to Guyader et al, 12 in the absence of liver biopsy, patients with serum ferritin <1000 mg/L were considered free of severe fibrosis.
Data recorded at the achievement of low body iron stores were extracted from LOGIFER and from logbooks previously given to patients at the time of diagnosis. They included serum iron, ferritin, and hemoglobin; transferrin saturation; and the number of grams of iron removed calculated as the number of liters of blood removed divided by 2.
Data recorded at inclusion were gathered from selfadministered questionnaires and from patient logbooks. Questionnaires included the following questions regarding the period of maintenance therapy: Do you consider that your athletic ability, your work ability, your libido decreased, improved or is stable? Do you consider that pain in your joints (shoulders, elbows, wrists, metacarpophalangeal and proximal interphalangeal joints, knees, ankles, and tarsus and metatarsophalangeal joints) decreased, improved or is stable? To answer these questions, patients were guided by a schematic representation of joints. Other questions were: Have you experienced joint replacement? Have you been diagnosed with cancer (hepatic/extrahepatic), diabetes or cardiovascular disease? What is your current weight? Dates and volumes of phlebotomies and corresponding values of transferrin saturation and serum iron, ferritin, and hemoglobin measured on samples drawn just before phlebotomies were collected from logbooks.
Calculation was made of exposure duration to transferrin saturation !50% (SAT50exp) and to serum ferritin !50 mg/L (FRT50exp). Curves of all available results of paired transferrin saturation and serum ferritin values were drawn according to time. SAT50exp and FRT50exp since the first achievement of low body iron stores were calculated as the number of years during which the curve had been above the transferrin saturation threshold of 50% and the serum ferritin level of 50 mg/L, respectively.
Statistical Analysis
First, SAT50exp and FRT50exp were analyzed as continuous variables. Then, because of the detection of threshold effects, they were transformed into categorical variables using receiver operating characteristic curve analysis to determine their best cutoff value in predicting symptoms. All univariate and multivariate analyses were adjusted on follow-up duration. Logistic models were used to identify initial and follow-up variables independently associated with clinical outcomes as reported by questionnaires and to identify the variables independently associated with SAT50exp and to FRT50exp among those collected at the time of diagnosis and at the initial achievement of low body iron stores. All variables for which statistical significance was <0.2 were introduced into models. P values < .05 were considered statistically significant. Quantitative variables were expressed as mean AE standard deviation and qualitative variables as number (%). Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
LOGIFER database was declared at the CNIL authority (National Committee for Informatics and Freedom). The study was authorized by the ethics committee of Rennes (number 11-27). All patients gave informed written consent.
Results
Study Population
From the 1932 C282Y homozygous patients prospectively recorded in LOGIFER at the date of study, 497 (25.7%) fulfilled eligibility criteria. Of these, 209 (42%) either no longer resided at the indicated address (n ¼ 47) or did not respond (n ¼ 162). Among the 288 (58%) responders, 22 were not included because of an insufficient number of transferrin saturation measurements. Finally, 266 of 497 persons (53.5%) were available for analysis. They had been on maintenance therapy for 13.5 AE 5.9 years. Their main characteristics are presented in Table 1 . With respect to initial clinical and biochemical presentation, the 162 patients who received but did not complete the questionnaire did not significantly differ from responders (Table 1) .
Relationship Between Paired Serum Ferritin and Transferrin Saturation Levels
A total of 7125 paired measurements of serum ferritin and transferrin saturation had been performed during follow-up, which corresponded to a mean number of 27.2 AE 15 samples per patient (range, 4-90) and to a mean number of 2.6 AE 9 samples per patient per year. When considering the threshold of 50 for the 2 tests, both were low in 49% of samples, and increased transferrin saturation was found in 41% of samples irrespective of serum ferritin levels and in 26% of samples with low serum ferritin levels.
Relationship Between Exposure Duration to Serum Ferritin !50 mg/L and Exposure Duration to Transferrin Saturation !50%, and Symptoms
The best cutoff values for the prediction of symptoms was 2.5 years with respect to FRT50exp and either 6 or 8 years with respect to SAT50exp ( Table 2 ). As shown in Table 3 , a significant association was found between increased joint symptoms and SAT50exp !6 years, decreased libido and SAT50exp !8 years, and decreased work ability and both FRT50exp !2.5 years and SAT50exp !8 years. There was only a trend for an association between decreased athletic ability and SAT50exp !6 years. To assess whether SAT50exp and FRT50exp were independently associated with general and joint symptoms, regression analysis was performed for each symptom associated with SAT50exp/FRT50exp at P < .20 at univariate analysis after adjustment for follow-up duration. All variables collected at diagnosis and at the achievement of low body iron stores, the duration and location of follow-up and answers to questionnaires were introduced into models together with SAT50exp and FRT50exp, when associated to SAT50exp/FRT50exp at P < .20. SAT50exp remained significantly associated with all symptoms and FRT50exp with decreased work ability only (Table 4) .
The same analyses were applied to exposure duration to transferrin saturation !75% (SAT75exp). The best cutoff value was 8 months. An independent association was found between SAT75exp and all clinical outcomes as was seen for SAT50exp (data not shown).
Relationship Between Exposure Duration to Serum Ferritin ‡50 mg/L and Exposure Duration to Transferrin Saturation ‡50% Mean FRT50exp was 3.2 AE 3.5 years and mean SAT50exp was 4.5 AE 3.4 years. As shown in Figure 1 , they were positively but weakly correlated (r ¼ 0.38 [95% confidence interval, 0.28-0.48]; P < .0001). Mean SAT50exp was 2.4 AE 2.3 years in the 34 patients with serum ferritin levels constantly <50 mg/L and then progressively increased parallel to FRT50exp (Figure 1 ).
Explanatory Factors of Exposure Duration to
Serum Ferritin ‡50 mg/L and Exposure Duration to Transferrin Saturation ‡50%
To identify, among variables collected at diagnosis, at the achievement of low body iron stores and during follow-up, those associated with FRT50exp and SAT50exp, logistic regression analysis was performed. As indicated in Table 5 , FRT50exp and SAT50exp were not explained by the same independent variables, except for follow-up duration (positive association) and BMI (positive association for FRT50exp and negative association for SAT50exp). Neither FRT50exp nor SAT50exp depended on the number of measurements of serum ferritin and transferrin saturation per year.
Discussion
This study is the first to document the course of serum ferritin and transferrin saturation levels in a large series of C282Y homozygotes on long-term maintenance therapy. Despite the fact there was an overall correlation between transferrin saturation and serum ferritin, the 2 variables could not be considered as collinear (ie, one could not be deduced from the other). The same was true for SAT50exp and FRT50exp. SAT50exp was found to be elevated (2.4 AE 2.3 years) in the 34 patients with serum ferritin levels constantly <50 mg/L and steadily increased parallel to FRT50exp (Figure 1) . Moreover, multivariate analyses indicated that FRT50exp and SAT50exp were not explained by the same variables (Table 5) . After adjustment for follow-up duration, SAT50exp was negatively associated with BMI and positively associated with tobacco smoking and older age at diagnosis. Decrease in serum transferrin levels, a common feature in hemochromatosis, is related to persisting down-regulation of transferrin synthesis by iron stores. Its extent depends on the rs3811647 polymorphism in the transferrin gene, which was identified as a significant modifier of iron metabolism in hemochromatosis. 13 Overweight was shown to be associated with lower transferrin saturation, especially in female C282Y homozygotes, 14 possibly through the production of hepcidin by visceral adipose tissue. 15, 16 Tobaccorelated chronic hypoxia could explain increased transferrin saturation caused by the negative effect of hypoxia-inducible factors on hepcidin synthesis. 17 After adjustment for follow-up duration, FRT50exp was positively associated with BMI, serum ferritin level at the end of initial achievement of low body iron stores, and follow-up outside the Liver Unit. The last 2 variables likely reflect different therapeutic habits. In contrast to SAT50exp, BMI was positively associated with FRT50exp. This is in line with the previous demonstration of increased serum ferritin levels in insulinresistance syndrome 18 for which BMI is a surrogate marker. These findings demonstrate that, in patients on maintenance therapy, transferrin saturation and serum ferritin measurements provide different information and that low serum ferritin levels do not guarantee normalization of transferrin saturation. The present study also showed that, unlike FRT50exp, SAT50exp was independently associated with all types of morbidity events, especially the worsening of metacarpophalangeal and proximal interphalangeal joint symptoms, which are considered as the most specifically related to hemochromatosis. 8 This is a key issue because, nowadays, hemochromatosis much more impairs the functional outcome, through general and joint symptoms, than survival. 1, 10 Hemochromatosis arthropathy is only partly related to the severity of iron burden, 19 because it may develop even when serum ferritin levels are moderately increased. 20 In addition, as previously stressed 8, 21, 22 and confirmed by the present study, ironrelated joint disease does not consistently respond to Table 3 . The best cutoff value differed according to symptoms: 6 years for joint symptoms and decreased athletic ability and 8 years for decreased work ability and decreased libido. phlebotomy therapy. In the study from Sahinbegovic et al, 23 only 13.6% of patients had improvement of their joint symptoms after iron removal. Even more, in a series of 18 regularly phlebotomized patients, Richette et al 24 found a paradoxical increase of a marker of cartilage degradation, CTXII, which could even suggest a negative impact of iron removal on cartilage metabolism. Whether this could be related to persisting elevated transferrin saturation levels despite low serum ferritin levels as suggested by the present study deserves attention. Hemochromatosis rheumatism mimics crystal arthropathies, which are mediated by inflammasome activation 25 and responsive to interleukine-1 inhibitor therapy. 26 Recently, a link between NTBI and inflammasome was suggested by the demonstration of an activation of the NLRP3 inflammasome through the induction of the cellular labile iron pool by ferric ammonium citrate in human monocytes. This was associated with a dosedependent increase in interleukin-1b and inhibited by iron chelation. 27 Unfortunately, for technical reasons, specific markers, such as NTBI and interleukins, were not available in the present series, but should be part of forthcoming studies assessing the putative role of persistently elevated transferrin saturation in the clinical outcome of hemochromatosis patients on long-term maintenance therapy.
The present results strongly suggest that, if maintenance therapy is performed, long-term exposure to elevated levels of transferrin saturation is associated with an increased occurrence of general and joint complications. This is not contrary to the hypothesis raised in the forthcoming Mi-Iron Melbourne study (Clinicaltrials.gov: NCT01631708) that it could be safer not to treat homozygotes with mild iron burden. Indeed, phlebotomies induce recurrent phases of iron hyperabsorption with increased transferrin saturation through the decrease of hepcidin production secondary to bursts of erythropoiesis. Therefore, it cannot be excluded that the cure could be worse than the disease in patients with mild iron burden.
Several issues about the present study have to be discussed. First, the study relied on a self-administered questionnaire, which forced us to resort to a few simple specific questions. All other data, including initial clinical presentation and biochemical follow-up data, were prospectively recorded from either LOGIFER or patient logbooks. Second, only 497 of 1932 patients (25.7%) were eligible. This was mainly explained by eligibility criteria including 1 paired measurement of serum ferritin and transferrin saturation per year at least. Requiring a higher number of transferrin saturation determinations per year would have been methodologically more relevant but would have resulted in a dramatic decrease of the population studied. Indeed, more and more patients have only serum ferritin determined because repeated transferrin saturation measurements are no longer reimbursed by the French national health system since 2000 and are not considered useful to manage therapeutic follow-up since the publication of the French 4 and international 3, 5, 6 guidelines. However, it is important to point out that FRT50exp and SAT50exp were not correlated with the number of measurements per year, but because they were, as logically expected, correlated with follow-up duration, all comparisons were made with adjustment on follow-up. Third, the marked biologic variability of transferrin saturation could have introduced a bias. However, assessment of SAT50exp and FRT50exp relied Figure 1 . Exposure duration to transferrin saturation !50% as years according to exposure duration to serum ferritin !50 mg/L as years (log) in the 266 C282Y homozygous patients.
on paired determinations made on samples drawn usually at the same time of day in a given subject, just before iron removal, and a long time after the previous phlebotomy, which should have likely minimized transferrin saturation variability. Fourth, the threshold of 50 mg/L for serum ferritin was chosen because it represents the ideal goal assigned to patients. That of 50% for transferrin saturation was proposed following the study of Loréal et al 28 who, in C282Y patients serially followed during phlebotomy therapy, showed that serum NTBI was found in almost all subjects when transferrin saturation exceeded 50% with a good correlation between transferrin saturation and NTBI levels. Similar data were found in patients with iron-loading anemias, 29 especially myelodysplastic syndromes. 30 Then, it can be assumed that most patients with continual SAT50exp were continuously exposed to NTBI. The threshold of 75% could also have been chosen in agreement with the study of Le Lan et al 31 and with clinical and experimental data collected in iron-loading anemias showing that labile plasma iron, the most redox active component of NTBI, occurs when transferrin saturation exceeds 75%, 29, 30 but this would have introduced too large a disequilibrium in sample size between the groups with short and long exposure to elevated transferrin saturation impairing statistical power. It is noteworthy that, when performing such an analysis, a similar association was found between SAT75exp and clinical outcomes. Interestingly, the best SAT75exp cutoff value was 8 months compared with 6 or 8 years for SAT50exp, which supports a dose-response relationship. Fifth, the response rate was 53%. This was not caused by a high number of deaths because a study of the vital status of all subjects recorded in the database was performed 1 year before launching the present study. 10 A significant number of patients were lost to follow-up (47 of 497) and 162 did not respond. These patients did not differ from those who completed the questionnaire with respect to disease severity at diagnosis, to follow-up duration or to age at inclusion (Table 1) . Then, even if the most worsened patients had been more prone to fill out questionnaires, this should have not influenced the association we found between the worsening of general and joint symptoms and SAT50exp.
Conclusions
The present study brings to light 2 original facts. First, it demonstrates that SAT50exp is independently associated with an increased risk of worsening of general and joint symptoms regardless of follow-up duration and of exposure duration to serum ferritin, except for decreased work ability. Second, it clearly indicates that maintaining serum ferritin levels below the threshold of 50 mg/L does not imply that transferrin saturation is under control. Because the current clinical outcome of treated hemochromatosis is mainly determined by general and joint symptoms, the present findings put into question the recommendations on the management of hemochromatosis. The same factors were associated with SAT50exp !8 years except for BMI and serum transferrin at diagnosis.
